AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] Salesforce, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Form 144 Overview: Krystal Biotech, Inc. (ticker KRYS) has filed a Form 144 indicating the proposed sale of 25,000 common shares through Morgan Stanley Smith Barney on or about 9 July 2025 on Nasdaq.

Key details

  • Aggregate market value: US$3,583,375.
  • Outstanding shares: 28,898,680.
  • Percentage of float: roughly 0.09 % of shares outstanding.
  • Seller’s position: Shares were acquired on 31 Mar 2017 as founders shares; no prior sales reported in the past three months.

The filing is a routine notice required under Rule 144 when an affiliate or insider intends to dispose of restricted or control securities. At <0.1 % of the company’s outstanding stock, the transaction is immaterial in scale and unlikely to meaningfully impact liquidity or corporate control. Nonetheless, insider sales can attract investor attention because they may be interpreted—rightly or wrongly—as signals about management’s outlook. The seller affirms they possess no undisclosed material adverse information, and no 10b5-1 trading plan adoption date is disclosed.

Investment view: This appears to be a low-impact, discretionary sale by an insider. Investors typically monitor cumulative insider activity and sale frequency rather than isolated filings of this size. No information in the document suggests operational, financial, or strategic changes at Krystal Biotech.

Panoramica del Modulo 144: Krystal Biotech, Inc. (ticker KRYS) ha presentato un Modulo 144 che indica la proposta vendita di 25.000 azioni ordinarie tramite Morgan Stanley Smith Barney intorno al 9 luglio 2025 sul Nasdaq.

Dettagli principali

  • Valore di mercato aggregato: 3.583.375 USD.
  • Azioni in circolazione: 28.898.680.
  • Percentuale del flottante: circa lo 0,09% delle azioni in circolazione.
  • Posizione del venditore: Le azioni sono state acquisite il 31 marzo 2017 come azioni dei fondatori; nessuna vendita precedente segnalata negli ultimi tre mesi.

La comunicazione è una notifica di routine richiesta dalla Regola 144 quando un affiliato o un insider intende disporre di titoli soggetti a restrizioni o di controllo. Con meno dello 0,1% del capitale sociale, la transazione è di entità irrilevante e difficilmente influenzerà la liquidità o il controllo societario. Tuttavia, le vendite da parte degli insider possono attirare l'attenzione degli investitori poiché possono essere interpretate � giustamente o meno � come segnali sull'outlook della direzione. Il venditore conferma di non possedere informazioni materiali negative non divulgate, e non è stata comunicata alcuna data di adozione di un piano di trading 10b5-1.

Visione d'investimento: Si tratta apparentemente di una vendita discrezionale a basso impatto da parte di un insider. Gli investitori solitamente monitorano l'attività cumulativa degli insider e la frequenza delle vendite piuttosto che singoli moduli di questa entità. Nessuna informazione nel documento suggerisce cambiamenti operativi, finanziari o strategici in Krystal Biotech.

Resumen del Formulario 144: Krystal Biotech, Inc. (símbolo KRYS) ha presentado un Formulario 144 indicando la venta propuesta de 25,000 acciones comunes a través de Morgan Stanley Smith Barney alrededor del 9 de julio de 2025 en Nasdaq.

Detalles clave

  • Valor de mercado agregado: 3.583.375 USD.
  • Acciones en circulación: 28.898.680.
  • Porcentaje del flotante: aproximadamente 0,09% de las acciones en circulación.
  • Posición del vendedor: Las acciones fueron adquiridas el 31 de marzo de 2017 como acciones de fundadores; no se reportaron ventas previas en los últimos tres meses.

La presentación es una notificación rutinaria requerida bajo la Regla 144 cuando un afiliado o insider planea disponer de valores restringidos o de control. Con menos del 0,1% del capital social, la transacción es de escala insignificante y es poco probable que afecte significativamente la liquidez o el control corporativo. No obstante, las ventas de insiders pueden atraer la atención de los inversores porque pueden interpretarse � correcta o erróneamente � como señales sobre la perspectiva de la dirección. El vendedor afirma no poseer información material adversa no divulgada, y no se revela fecha de adopción de un plan de negociación 10b5-1.

Perspectiva de inversión: Esto parece ser una venta discrecional de bajo impacto por parte de un insider. Los inversores suelen monitorear la actividad acumulada de insiders y la frecuencia de ventas en lugar de presentaciones aisladas de este tamaño. Ninguna información en el documento sugiere cambios operativos, financieros o estratégicos en Krystal Biotech.

í� 144 개요: Krystal Biotech, Inc.(티커 KRYS)ëŠ� 2025ë…� 7ì›� 9ì¼ê²½ 나스닥ì—ì„� Morgan Stanley Smith Barneyë¥� 통해 25,000 보통ì£� 매ê°ì� 제안하는 í� 144ë¥� 제출했습니다.

주요 내용

  • ì´� 시가ì´ì•¡: 3,583,375 달러.
  • 발행 ì£¼ì‹ ìˆ�: 28,898,680ì£�.
  • 유통 ì£¼ì‹ ë¹„ìœ¨: ì•� 0.09%.
  • íŒë§¤ìž� ì§€ë¶�: 2017ë…� 3ì›� 31ì� 창업ìž� 주ì‹ìœ¼ë¡œ ì·¨ë“; 최근 3개월 ë‚� 별ë„ì� ë§¤ë„ ë‚´ì—­ ì—†ìŒ.

ì� ì œì¶œì€ ë‚´ë¶€ìž� ë˜ëŠ” 계열사가 제한 주ì‹ì´ë‚˜ 통제 주ì‹ì� 처분하려 í•� ë•� 규칙 144ì—� ë”°ë¼ ìš”êµ¬ë˜ëŠ” ì¼ìƒì ì¸ 통지입니ë‹�. 회사 발행 주ì‹ì� 0.1% 미만으로, 거래 규모ëŠ� 미미í•� 수준ì´ë©° 유ë™ì„±ì´ë‚� 기업 통제ì—� í� ì˜í–¥ì� 미치지 ì•Šì„ ê²ƒìœ¼ë¡� 보입니다. 다만, ë‚´ë¶€ìž� 매ë„ëŠ� ê²½ì˜ì§� ì „ë§ì—� 대í•� 신호ë¡� í•´ì„ë� ìˆ� 있어 투ìžìž� ê´€ì‹¬ì„ ë� ìˆ� 있습니다. íŒë§¤ìžëŠ” 공개ë˜ì§€ ì•Šì€ ì¤‘ëŒ€í•� ë¶€ì •ì  ì •ë³´ë¥� 보유하지 않으ë©�, 10b5-1 거래 ê³„íš ì±„íƒì¼ì€ 공개ë˜ì§€ 않았습니ë‹�.

íˆ¬ìž ê´€ì �: ì´ëŠ” ë‚´ë¶€ìžì˜ ì €ì˜í–¥ ìž„ì˜ ë§¤ë„ë¡� 보입니다. 투ìžìžë“¤ì€ ì¼ë°˜ì ìœ¼ë¡� ë‹¨ì¼ ì œì¶œ ê±´ë³´ë‹� ëˆ„ì  ë‚´ë¶€ìž� 활ë™ê³� ë§¤ë„ ë¹ˆë„ë¥� 주시합니ë‹�. 문서ìƒ� Krystal Biotechì� ìš´ì˜, 재무, ì „ëžµì � ë³€í™”ì— ê´€í•� ì •ë³´ëŠ� 없습니다.

Présentation du Formulaire 144 : Krystal Biotech, Inc. (symbole KRYS) a déposé un Formulaire 144 indiquant la vente proposée de 25 000 actions ordinaires via Morgan Stanley Smith Barney aux alentours du 9 juillet 2025 sur le Nasdaq.

Détails clés

  • Valeur de marché agrégée : 3 583 375 USD.
  • Actions en circulation : 28 898 680.
  • Pourcentage du flottant : environ 0,09 % des actions en circulation.
  • Position du vendeur : Les actions ont été acquises le 31 mars 2017 en tant qu'actions de fondateurs ; aucune vente antérieure signalée au cours des trois derniers mois.

Le dépôt est une notification de routine requise par la règle 144 lorsqu'un affilié ou un initié prévoit de céder des titres restreints ou contrôlés. Avec moins de 0,1 % des actions en circulation, la transaction est de portée négligeable et peu susceptible d'affecter significativement la liquidité ou le contrôle de l'entreprise. Néanmoins, les ventes d'initiés peuvent attirer l'attention des investisseurs car elles peuvent être interprétées � à tort ou à raison � comme des signaux sur les perspectives de la direction. Le vendeur affirme ne pas détenir d'informations défavorables matérielles non divulguées, et aucune date d'adoption d'un plan de trading 10b5-1 n'est communiquée.

Point de vue d'investissement : Cela semble être une vente discrétionnaire à faible impact d'un initié. Les investisseurs surveillent généralement l'activité cumulée des initiés et la fréquence des ventes plutôt que des dépôts isolés de cette taille. Aucune information dans le document ne suggère de changements opérationnels, financiers ou stratégiques chez Krystal Biotech.

Überblick Formular 144: Krystal Biotech, Inc. (Ticker KRYS) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 25.000 Stammaktien über Morgan Stanley Smith Barney etwa am 9. Juli 2025 an der Nasdaq ankündigt.

Wichtige Details

  • Gesamtmarktwert: 3.583.375 USD.
  • Ausstehende Aktien: 28.898.680.
  • Prozentualer Anteil am Free Float: ca. 0,09 % der ausstehenden Aktien.
  • Position des Verkäufers: Aktien wurden am 31. März 2017 als ³Ò°ùü²Ô»å±ð°ù²¹°ì³Ù¾±±ð²Ô erworben; in den letzten drei Monaten keine vorherigen Verkäufe gemeldet.

Die Einreichung ist eine routinemäßige Mitteilung gemäß Regel 144, wenn ein Insider oder Affiliate beabsichtigt, beschränkte oder kontrollierte Wertpapiere zu veräußern. Mit weniger als 0,1 % der ausstehenden Aktien ist die Transaktion von unwesentlicher Größenordnung und wird voraussichtlich weder die Liquidität noch die Unternehmensführung wesentlich beeinflussen. Dennoch können Insiderverkäufe die Aufmerksamkeit der Investoren auf sich ziehen, da sie � zu Recht oder zu Unrecht � als Signale für die Einschätzung des Managements interpretiert werden können. Der Verkäufer bestätigt, keine nicht offengelegten, wesentlichen negativen Informationen zu besitzen, und es wird kein Datum für die Einführung eines 10b5-1 Handelsplans angegeben.

Investmentansicht: Dies scheint ein unbedeutender, diskretionärer Verkauf eines Insiders zu sein. Investoren beobachten typischerweise die kumulative Insideraktivität und Verkaufshäufigkeit, nicht einzelne Meldungen dieser Größenordnung. Im Dokument finden sich keine Hinweise auf operative, finanzielle oder strategische Veränderungen bei Krystal Biotech.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Routine Form 144 for 25 k shares (0.09 % float); insignificant on valuation, mildly negative sentiment due to insider selling.

From a capital-markets perspective, the proposed sale represents less than 0.1 % of the 28.9 million shares outstanding—far below any threshold likely to pressure daily trading volumes. The US$3.6 million notional value is modest for a company with a multi-billion-dollar market cap, implying negligible dilution or liquidity concerns. While insider sales often trigger knee-jerk reactions, the lack of accompanying operational disclosures, combined with the founders shares origin, suggests personal liquidity rather than strategic repositioning. I classify the filing as not impactful to earnings outlook or valuation multiples.

TL;DR Governance risk minimal; standard Rule 144 compliance, no aggregation issues, no recent insider sales.

The filer certifies absence of undisclosed adverse information and reports no sales in the preceding three months, satisfying Rule 144(e) aggregation limits. There is no indication of a 10b5-1 plan, so timing is discretionary but still permissible. Given the fractional share percentage, board-level governance implications are negligible. Investors should continue to track overall insider activity trends, but this single notice does not alter governance risk assessments.

Panoramica del Modulo 144: Krystal Biotech, Inc. (ticker KRYS) ha presentato un Modulo 144 che indica la proposta vendita di 25.000 azioni ordinarie tramite Morgan Stanley Smith Barney intorno al 9 luglio 2025 sul Nasdaq.

Dettagli principali

  • Valore di mercato aggregato: 3.583.375 USD.
  • Azioni in circolazione: 28.898.680.
  • Percentuale del flottante: circa lo 0,09% delle azioni in circolazione.
  • Posizione del venditore: Le azioni sono state acquisite il 31 marzo 2017 come azioni dei fondatori; nessuna vendita precedente segnalata negli ultimi tre mesi.

La comunicazione è una notifica di routine richiesta dalla Regola 144 quando un affiliato o un insider intende disporre di titoli soggetti a restrizioni o di controllo. Con meno dello 0,1% del capitale sociale, la transazione è di entità irrilevante e difficilmente influenzerà la liquidità o il controllo societario. Tuttavia, le vendite da parte degli insider possono attirare l'attenzione degli investitori poiché possono essere interpretate � giustamente o meno � come segnali sull'outlook della direzione. Il venditore conferma di non possedere informazioni materiali negative non divulgate, e non è stata comunicata alcuna data di adozione di un piano di trading 10b5-1.

Visione d'investimento: Si tratta apparentemente di una vendita discrezionale a basso impatto da parte di un insider. Gli investitori solitamente monitorano l'attività cumulativa degli insider e la frequenza delle vendite piuttosto che singoli moduli di questa entità. Nessuna informazione nel documento suggerisce cambiamenti operativi, finanziari o strategici in Krystal Biotech.

Resumen del Formulario 144: Krystal Biotech, Inc. (símbolo KRYS) ha presentado un Formulario 144 indicando la venta propuesta de 25,000 acciones comunes a través de Morgan Stanley Smith Barney alrededor del 9 de julio de 2025 en Nasdaq.

Detalles clave

  • Valor de mercado agregado: 3.583.375 USD.
  • Acciones en circulación: 28.898.680.
  • Porcentaje del flotante: aproximadamente 0,09% de las acciones en circulación.
  • Posición del vendedor: Las acciones fueron adquiridas el 31 de marzo de 2017 como acciones de fundadores; no se reportaron ventas previas en los últimos tres meses.

La presentación es una notificación rutinaria requerida bajo la Regla 144 cuando un afiliado o insider planea disponer de valores restringidos o de control. Con menos del 0,1% del capital social, la transacción es de escala insignificante y es poco probable que afecte significativamente la liquidez o el control corporativo. No obstante, las ventas de insiders pueden atraer la atención de los inversores porque pueden interpretarse � correcta o erróneamente � como señales sobre la perspectiva de la dirección. El vendedor afirma no poseer información material adversa no divulgada, y no se revela fecha de adopción de un plan de negociación 10b5-1.

Perspectiva de inversión: Esto parece ser una venta discrecional de bajo impacto por parte de un insider. Los inversores suelen monitorear la actividad acumulada de insiders y la frecuencia de ventas en lugar de presentaciones aisladas de este tamaño. Ninguna información en el documento sugiere cambios operativos, financieros o estratégicos en Krystal Biotech.

í� 144 개요: Krystal Biotech, Inc.(티커 KRYS)ëŠ� 2025ë…� 7ì›� 9ì¼ê²½ 나스닥ì—ì„� Morgan Stanley Smith Barneyë¥� 통해 25,000 보통ì£� 매ê°ì� 제안하는 í� 144ë¥� 제출했습니다.

주요 내용

  • ì´� 시가ì´ì•¡: 3,583,375 달러.
  • 발행 ì£¼ì‹ ìˆ�: 28,898,680ì£�.
  • 유통 ì£¼ì‹ ë¹„ìœ¨: ì•� 0.09%.
  • íŒë§¤ìž� ì§€ë¶�: 2017ë…� 3ì›� 31ì� 창업ìž� 주ì‹ìœ¼ë¡œ ì·¨ë“; 최근 3개월 ë‚� 별ë„ì� ë§¤ë„ ë‚´ì—­ ì—†ìŒ.

ì� ì œì¶œì€ ë‚´ë¶€ìž� ë˜ëŠ” 계열사가 제한 주ì‹ì´ë‚˜ 통제 주ì‹ì� 처분하려 í•� ë•� 규칙 144ì—� ë”°ë¼ ìš”êµ¬ë˜ëŠ” ì¼ìƒì ì¸ 통지입니ë‹�. 회사 발행 주ì‹ì� 0.1% 미만으로, 거래 규모ëŠ� 미미í•� 수준ì´ë©° 유ë™ì„±ì´ë‚� 기업 통제ì—� í� ì˜í–¥ì� 미치지 ì•Šì„ ê²ƒìœ¼ë¡� 보입니다. 다만, ë‚´ë¶€ìž� 매ë„ëŠ� ê²½ì˜ì§� ì „ë§ì—� 대í•� 신호ë¡� í•´ì„ë� ìˆ� 있어 투ìžìž� ê´€ì‹¬ì„ ë� ìˆ� 있습니다. íŒë§¤ìžëŠ” 공개ë˜ì§€ ì•Šì€ ì¤‘ëŒ€í•� ë¶€ì •ì  ì •ë³´ë¥� 보유하지 않으ë©�, 10b5-1 거래 ê³„íš ì±„íƒì¼ì€ 공개ë˜ì§€ 않았습니ë‹�.

íˆ¬ìž ê´€ì �: ì´ëŠ” ë‚´ë¶€ìžì˜ ì €ì˜í–¥ ìž„ì˜ ë§¤ë„ë¡� 보입니다. 투ìžìžë“¤ì€ ì¼ë°˜ì ìœ¼ë¡� ë‹¨ì¼ ì œì¶œ ê±´ë³´ë‹� ëˆ„ì  ë‚´ë¶€ìž� 활ë™ê³� ë§¤ë„ ë¹ˆë„ë¥� 주시합니ë‹�. 문서ìƒ� Krystal Biotechì� ìš´ì˜, 재무, ì „ëžµì � ë³€í™”ì— ê´€í•� ì •ë³´ëŠ� 없습니다.

Présentation du Formulaire 144 : Krystal Biotech, Inc. (symbole KRYS) a déposé un Formulaire 144 indiquant la vente proposée de 25 000 actions ordinaires via Morgan Stanley Smith Barney aux alentours du 9 juillet 2025 sur le Nasdaq.

Détails clés

  • Valeur de marché agrégée : 3 583 375 USD.
  • Actions en circulation : 28 898 680.
  • Pourcentage du flottant : environ 0,09 % des actions en circulation.
  • Position du vendeur : Les actions ont été acquises le 31 mars 2017 en tant qu'actions de fondateurs ; aucune vente antérieure signalée au cours des trois derniers mois.

Le dépôt est une notification de routine requise par la règle 144 lorsqu'un affilié ou un initié prévoit de céder des titres restreints ou contrôlés. Avec moins de 0,1 % des actions en circulation, la transaction est de portée négligeable et peu susceptible d'affecter significativement la liquidité ou le contrôle de l'entreprise. Néanmoins, les ventes d'initiés peuvent attirer l'attention des investisseurs car elles peuvent être interprétées � à tort ou à raison � comme des signaux sur les perspectives de la direction. Le vendeur affirme ne pas détenir d'informations défavorables matérielles non divulguées, et aucune date d'adoption d'un plan de trading 10b5-1 n'est communiquée.

Point de vue d'investissement : Cela semble être une vente discrétionnaire à faible impact d'un initié. Les investisseurs surveillent généralement l'activité cumulée des initiés et la fréquence des ventes plutôt que des dépôts isolés de cette taille. Aucune information dans le document ne suggère de changements opérationnels, financiers ou stratégiques chez Krystal Biotech.

Überblick Formular 144: Krystal Biotech, Inc. (Ticker KRYS) hat ein Formular 144 eingereicht, das den geplanten Verkauf von 25.000 Stammaktien über Morgan Stanley Smith Barney etwa am 9. Juli 2025 an der Nasdaq ankündigt.

Wichtige Details

  • Gesamtmarktwert: 3.583.375 USD.
  • Ausstehende Aktien: 28.898.680.
  • Prozentualer Anteil am Free Float: ca. 0,09 % der ausstehenden Aktien.
  • Position des Verkäufers: Aktien wurden am 31. März 2017 als ³Ò°ùü²Ô»å±ð°ù²¹°ì³Ù¾±±ð²Ô erworben; in den letzten drei Monaten keine vorherigen Verkäufe gemeldet.

Die Einreichung ist eine routinemäßige Mitteilung gemäß Regel 144, wenn ein Insider oder Affiliate beabsichtigt, beschränkte oder kontrollierte Wertpapiere zu veräußern. Mit weniger als 0,1 % der ausstehenden Aktien ist die Transaktion von unwesentlicher Größenordnung und wird voraussichtlich weder die Liquidität noch die Unternehmensführung wesentlich beeinflussen. Dennoch können Insiderverkäufe die Aufmerksamkeit der Investoren auf sich ziehen, da sie � zu Recht oder zu Unrecht � als Signale für die Einschätzung des Managements interpretiert werden können. Der Verkäufer bestätigt, keine nicht offengelegten, wesentlichen negativen Informationen zu besitzen, und es wird kein Datum für die Einführung eines 10b5-1 Handelsplans angegeben.

Investmentansicht: Dies scheint ein unbedeutender, diskretionärer Verkauf eines Insiders zu sein. Investoren beobachten typischerweise die kumulative Insideraktivität und Verkaufshäufigkeit, nicht einzelne Meldungen dieser Größenordnung. Im Dokument finden sich keine Hinweise auf operative, finanzielle oder strategische Veränderungen bei Krystal Biotech.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Benioff Marc

(Last) (First) (Middle)
415 MISSION STREET
3RD FLOOR

(Street)
SAN FRANCISCO CA 94105

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Salesforce, Inc. [ CRM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chair and CEO
3. Date of Earliest Transaction (Month/Day/Year)
07/08/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/08/2025 M(1) 2,250 A $161.5 11,864,707 D(2)
Common Stock 07/08/2025 S(1) 382 D $270.6061(3) 11,864,325 D(2)
Common Stock 07/08/2025 S(1) 123 D $271.6543(4) 11,864,202 D(2)
Common Stock 07/08/2025 S(1) 837 D $273.4855(5) 11,863,365 D(2)
Common Stock 07/08/2025 S(1) 536 D $274.2949(6) 11,862,829 D(2)
Common Stock 07/08/2025 S(1) 255 D $275.216(7) 11,862,574 D(2)
Common Stock 07/08/2025 S(1) 117 D $276.168(8) 11,862,457 D(2)
Common Stock 107,000 I By Trust
Common Stock 10,000,000 I(9) By Marc Benioff Fund LLC
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-qualified Stock Option (Right to Buy) $161.5 07/08/2025 M(1) 2,250 03/22/2020(10) 03/22/2026 Common Stock 2,250 $0 184,622 D
Explanation of Responses:
1. As indicated by the checkbox above, this transaction was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 9, 2025.
2. Shares held in the reporting person's name or in the Marc R. Benioff Revocable Trust.
3. Weighted average price. These shares were sold in multiple transactions at prices ranging from $270.0908 to $271.0000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
4. Weighted average price. These shares were sold in multiple transactions at prices ranging from $271.2886 to $271.9930 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
5. Weighted average price. These shares were sold in multiple transactions at prices ranging from $272.8300 to $273.8200 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
6. Weighted average price. These shares were sold in multiple transactions at prices ranging from $273.8300 to $274.7852 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
7. Weighted average price. These shares were sold in multiple transactions at prices ranging from $274.9100 to $275.8200 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
8. Weighted average price. These shares were sold in multiple transactions at prices ranging from $275.9638 to $276.4070 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
9. Shares held in the Marc Benioff Fund LLC (the "Fund"). Fund interests are held in the reporting person's name or in trust.
10. Option vests over four years at the rate of 25% on March 22, 2020, the first anniversary of the holder's date of grant, with the balance vesting in equal monthly installments over the remaining 36 months.
/s/ Sarah Dale, Attorney-in-Fact for Marc Benioff 07/09/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Krystal Biotech (KRYS) shares are being sold under this Form 144?

The notice covers 25,000 common shares.

What is the market value of the proposed KRYS share sale?

The aggregate market value is US$3,583,375.

What percentage of Krystal Biotech’s outstanding shares does 25,000 represent?

Approximately 0.09 % of the 28,898,680 shares outstanding.

When is the KRYS insider planning to sell the shares?

The approximate sale date stated is 09 July 2025.

Which broker will handle the KRYS share sale?

The broker is Morgan Stanley Smith Barney LLC.

Were any other KRYS shares sold by this insider in the last three months?

No. The filing states “Nothing to Report� for prior three-month sales.
Salesforce Com Inc

NYSE:CRM

CRM Rankings

CRM Latest News

CRM Latest SEC Filings

CRM Stock Data

259.95B
931.03M
2.63%
82.78%
1%
Software - Application
Services-prepackaged Software
United States
SAN FRANCISCO